Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Vericel Corporation’s Chief Operating Officer Michael Halpin reported equity compensation and related share movements. On February 19, 2026, he was granted stock options for 52,500 shares and 21,000 Restricted Stock Units (RSUs), all held directly. These options begin vesting on February 19, 2026 in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030.
On February 18, 2026, RSUs granted in 2022 and 2023 vested, converting into common stock. In connection with these vestings, the company withheld 2,486 shares at a fair market value of $36.82 per share and 1,812 shares at $37.41 per share to cover tax obligations. These transactions reflect compensation vesting and tax withholding rather than open-market buying or selling.
Vericel director Kevin F. McLaughlin reported an option exercise and share sale. On February 11, 2026, he exercised 7,000 stock options with a $2.63 exercise price, receiving 7,000 shares of common stock and bringing his direct holdings to 22,100 shares.
That same day, he sold 7,000 common shares in an open-market transaction at $34.66 per share under a pre-established Rule 10b5-1 trading plan, leaving him with 15,100 directly owned shares. Following the exercise, he also held 3,500 stock options at a $2.63 exercise price expiring on May 3, 2027, from an original grant covering 17,500 shares.
A shareholder has filed a Form 144 notice to sell 7,000 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ. The shares have an stated aggregate market value of $249,340.00. These shares were acquired via an option granted on 05/03/2017 and are scheduled for sale with an approximate sale date of 02/11/2026, with payment described as in cash.
Vericel Corporation filed a report stating it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for January 14, 2026, at 11:15 a.m. Pacific Time. In connection with the conference, the company issued a January 13, 2026 press release that provides preliminary, unaudited financial information for full-year 2025.
The press release includes estimates of Vericel’s 2025 revenue, net income, gross margin percentage, adjusted EBITDA margin, and its cash and investments balance as of December 31, 2025, along with additional financial and business updates. The company emphasizes that these figures are preliminary, have not been audited or reviewed by PricewaterhouseCoopers LLP, and may change, so stockholders are cautioned not to place undue reliance on them.
Vericel Corp’s Chief Operating Officer Michael Halpin reported option exercises and share sales. On 01/07/2026 he exercised 10,000 stock options at $16.66 per share, receiving 10,000 shares of common stock. He then sold 10,000 common shares at $40.48 per share in an automatic transaction under a Rule 10b5-1 trading plan adopted on November 19, 2024.
After these transactions, Halpin directly owned 16,080 shares of Vericel common stock and 46,250 stock options. The reported options were originally part of a grant representing the right to purchase 76,250 shares that vested in equal quarterly installments starting on May 6, 2019, contingent on continued service to the company.
This Form 144 notice discloses a planned sale of 10,000 shares of common stock in the issuer by Michael Halpin. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of 404,832.95.
The 10,000 shares were acquired on 01/07/2026 via a cash exercise of a stock option that was granted on 02/06/2019 by the issuer. The notice also reports that, in the past three months, Halpin sold additional common shares: 7,358 shares on 11/06/2025 for gross proceeds of 297,774.58, and 2,642 shares on 11/11/2025 for gross proceeds of 106,759.79.
By signing the notice, the selling holder represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Vericel Corporation’s chief human resources officer reported the vesting of equity awards on July 22, 2025. Restricted stock units granted on July 22, 2024 converted into 2,625 shares of common stock, with the issuer withholding 771 shares to satisfy tax obligations at a fair market value of $37.98 per share. After these transactions, the officer directly owns 1,854 common shares and 7,875 restricted stock units, each RSU representing the right to receive one Vericel share. The remaining RSUs from this grant are scheduled to vest in annual installments on July 22, 2026, July 22, 2027, and July 22, 2028.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin on 11/11/2025. He exercised a stock option for 2,642 shares at $16.66 (code M) and sold 2,642 shares at $40.41 (code S). The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, he directly owned 15,932 shares. Derivative holdings included 56,250 stock options. The footnotes note prior shares acquired under the 2015 Employee Stock Purchase Plan and the vesting schedule of the option grant.
Vericel (VCEL) reported an insider transaction by a director on 11/10/2025. The director exercised 7,000 stock options at an exercise price of $2.63 (code M) and sold 7,000 shares at an average price of $38.59 (code S) under a Rule 10b5-1 trading plan adopted on March 11, 2024.
Following these transactions, the director reported 15,100 shares beneficially owned directly and 10,500 options remaining beneficially owned. The options exercised were part of a grant from May 3, 2017 that vested in equal monthly installments over one year contingent on continued service.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin. On 11/06/2025, he exercised 7,358 stock options at $16.66 per share and sold 7,358 common shares at $40.47, with the sale executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, Halpin directly beneficially owned 15,932 common shares. His remaining derivative holdings included 58,892 stock options. Footnotes note prior shares acquired under the company’s 2015 Employee Stock Purchase Plan.